{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:39:35Z","timestamp":1789727975229,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Pneumocystis jirovecii<\/jats:italic>\n                      pneumonia (PCP) in non-human immunodeficiency virus (HIV) patients is associated with high morbidity and mortality. Although prior studies have linked delayed treatment to worse outcomes, they are often limited by small sample sizes and inadequate adjustment for confounders. Therefore, we evaluated whether early treatment after hospital admission improves mortality in non-HIV PCP, adjusting for patient characteristics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multi-center, retrospective, observational cohort study included non-HIV PCP patients treated between January 2006 and March 2021 at three institutions. Participants were divided into the early treatment (initiated within 2 days) and late treatment (initiated between days 3 and 7) groups. The primary endpoint was 30-day mortality, and the secondary endpoints were 180-day mortality. Propensity score weighting was used to adjust for patient background.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-four patients in the early treatment group and 43 in the late treatment group were evaluated. The average time-to-treatment for the early and late treatment groups was 0.13 days and 3.63 days, respectively. After adjusting for patient characteristics, there were no significant differences in 30-day mortality (14.0% vs. 8.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.307) or 180-day mortality (21.5% vs. 17.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.600) between the early and late treatment groups. In a subgroup analysis of cases requiring oxygen supplementation, 30-day and 180-day mortality also showed no significant differences between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study emphasizes the importance of accurate diagnosis and tailored management based on disease severity rather than immediate empirical treatment, as early treatment initiation was not significantly associated with 30-day or 180-day mortality in non-HIV PCP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-10933-3","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T14:53:34Z","timestamp":1744728814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Haruka","family":"Fujioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watari","family":"Tomohisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"2","key":"10933_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4046\/trd.2020.0015","volume":"83","author":"S Tasaka","year":"2020","unstructured":"Tasaka S. Recent advances in the diagnosis and management of <\u2009i\u2009>\u2009pneumocystis\u2009pneumonia. Tuberc Respir Dis. 2020;83(2):132.","journal-title":"Tuberc Respir Dis"},{"issue":"24","key":"10933_CR2","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMra032588","volume":"350","author":"CF Thomas Jr","year":"2004","unstructured":"Thomas CF Jr., Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"10933_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1056\/NEJM199808063390612","volume":"339","author":"SH Michaels","year":"1998","unstructured":"Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339(6):405\u20136.","journal-title":"N Engl J Med"},{"key":"10933_CR4","doi-asserted-by":"crossref","unstructured":"Pereira-D\u00edaz E, Moreno-Verdejo F, De La Horra C, Guerrero JA, Calder\u00f3n EJ, Medrano FJ. Changing trends in the epidemiology and risk factors of Pneumocystis pneumonia in Spain. Front Public Health 2019, 7.","DOI":"10.3389\/fpubh.2019.00275"},{"issue":"35","key":"10933_CR5","doi-asserted-by":"publisher","first-page":"59729","DOI":"10.18632\/oncotarget.19927","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Su L, Jiang SJ, Qu H. Risk factors for mortality from Pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis. Oncotarget. 2017;8(35):59729\u201339.","journal-title":"Oncotarget"},{"issue":"1","key":"10933_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jinf.2014.02.015","volume":"69","author":"SJ Kim","year":"2014","unstructured":"Kim SJ, Lee J, Cho YJ, Park YS, Lee CH, Yoon HI, Lee SM, Yim JJ, Lee JH, Yoo CG, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect. 2014;69(1):88\u201395.","journal-title":"J Infect"},{"issue":"9","key":"10933_CR7","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3201\/eid2009.131668","volume":"20","author":"A Roux","year":"2014","unstructured":"Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, Maubon D, Debourgogne A, Le Gal S, Dalle F, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis. 2014;20(9):1490\u20137.","journal-title":"Emerg Infect Dis"},{"key":"10933_CR8","doi-asserted-by":"crossref","unstructured":"Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. Journal of microbiology, immunology, and infection\u2009=\u2009Wei mian yu gan ran za zhi 2014, 47(1):42\u201347.","DOI":"10.1016\/j.jmii.2012.08.024"},{"issue":"6\u20137","key":"10933_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/00365540601150497","volume":"39","author":"UM Overgaard","year":"2007","unstructured":"Overgaard UM, Helweg-Larsen J. Pneumocystis Jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002\u20132004. Scand J Infect Dis. 2007;39(6\u20137):589\u201395.","journal-title":"Scand J Infect Dis"},{"issue":"6","key":"10933_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10156-012-0441-4","volume":"18","author":"N Asai","year":"2012","unstructured":"Asai N, Motojima S, Ohkuni Y, Matsunuma R, Nakashima K, Iwasaki T, Nakashita T, Otsuka Y, Kaneko N. Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. J Infect Chemother. 2012;18(6):898\u2013905.","journal-title":"J Infect Chemother"},{"issue":"6","key":"10933_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jmii.2017.07.007","volume":"51","author":"K Nakashima","year":"2018","unstructured":"Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S, Misawa M, Otsuka Y, Motojima S. Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study. J Microbiol Immunol Infect = Wei Mian Yu Gan Ran Za Zhi. 2018;51(6):810\u201320.","journal-title":"J Microbiol Immunol Infect = Wei Mian Yu Gan Ran Za Zhi"},{"issue":"Suppl 2","key":"10933_CR12","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1093\/cid\/ciaa1805","volume":"72","author":"K Lagrou","year":"2021","unstructured":"Lagrou K, Chen S, Masur H, Viscoli C, Decker CF, Pagano L, Groll AH. Pneumocystis jirovecii disease: basis for the revised EORTC\/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2021;72(Suppl 2):S114\u201320.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"18","key":"10933_CR13","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1056\/NEJMc070728","volume":"357","author":"M Harigai","year":"2007","unstructured":"Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia under Anti-Tumor necrosis factor therapy study G: Pneumocystis pneumonia associated with Infliximab in Japan. N Engl J Med. 2007;357(18):1874\u20136.","journal-title":"N Engl J Med"},{"issue":"9","key":"10933_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cmi.2020.05.024","volume":"26","author":"O Del Corpo","year":"2020","unstructured":"Del Corpo O, Butler-Laporte G, Sheppard DC, Cheng MP, McDonald EG, Lee TC. Diagnostic accuracy of serum (1\u20133)-\u03b2-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(9):1137\u201343.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10933_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1186\/s12879-021-06895-x","volume":"21","author":"J Taniguchi","year":"2021","unstructured":"Taniguchi J, Nakashima K, Matsui H, Watari T, Otsuki A, Ito H, Otsuka Y. Low cut-off value of serum (1,3)-beta-D-glucan for the diagnosis of Pneumocystis pneumonia in non-HIV patients: a retrospective cohort study. BMC Infect Dis. 2021;21(1):1200.","journal-title":"BMC Infect Dis"},{"key":"10933_CR16","doi-asserted-by":"crossref","unstructured":"Nagai T, Matsui H, Fujioka H, Homma Y, Otsuki A, Ito H, Ohmura S, Miyamoto T, Shichi D, Tomohisa W et al. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV. CHEST 2024, 165(1):58\u201367.","DOI":"10.1016\/j.chest.2023.08.009"},{"issue":"2","key":"10933_CR17","doi-asserted-by":"publisher","first-page":"e0246296","DOI":"10.1371\/journal.pone.0246296","volume":"16","author":"T-O Kim","year":"2021","unstructured":"Kim T-O, Lee J-K, Kwon Y-S, Kim Y-I, Lim S-C, Kim M-S, Kho BG, Park C-K, Oh I-J, Kim Y-C, et al. Clinical characteristics and prognosis of patients with Pneumocystis jirovecii pneumonia without a compromised illness. PLoS ONE. 2021;16(2):e0246296.","journal-title":"PLoS ONE"},{"issue":"1","key":"10933_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12931-019-1188-6","volume":"20","author":"RE Ko","year":"2019","unstructured":"Ko RE, Na SJ, Huh K, Suh GY, Jeon K. Association of time-to-treatment with outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. Respir Res. 2019;20(1):213.","journal-title":"Respir Res"},{"key":"10933_CR19","doi-asserted-by":"crossref","unstructured":"Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P. th European Conference on Infections in Leukemia ajvoTEGfB, Marrow Transplantation TEOfR, Treatment of Cancer tIIHS, The European L: ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 2016, 71(9):2405\u20132413.","DOI":"10.1093\/jac\/dkw158"},{"issue":"1","key":"10933_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","volume":"183","author":"AH Limper","year":"2011","unstructured":"Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, Davies SF, Dismukes WE, Hage CA, Marr KA, et al. An official American thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96\u2013128.","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"10933_CR21","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJM199011223232131","volume":"323","author":"Consensus statement on the use","year":"1990","unstructured":"Consensus statement on the use. Of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323(21):1500\u20134.","journal-title":"N Engl J Med"},{"key":"10933_CR22","doi-asserted-by":"crossref","unstructured":"Kosaka M, Ushiki A, Ikuyama Y, Hirai K, Matsuo A, Hachiya T, Hanaoka M. A Four-Center retrospective study of the efficacy and toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the treatment of Pneumocystis pneumonia in patients without HIV infection. Antimicrob Agents Chemother 2017, 61(12).","DOI":"10.1128\/AAC.01173-17"},{"issue":"1","key":"10933_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"key":"10933_CR24","unstructured":"Common Terminology. Criteria for Adverse Events (CTCAE) Version 5.0.November 27, 2017 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf Date accessed: March 20, 2025"},{"issue":"28","key":"10933_CR25","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"6","key":"10933_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hern\u00e1n MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656\u201364.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10933_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccc.2020.09.001","volume":"37","author":"SK Seo","year":"2021","unstructured":"Seo SK, Liu C, Dadwal SS. Infectious disease complications in patients with cancer. Crit Care Clin. 2021;37(1):69\u201384.","journal-title":"Crit Care Clin"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10933-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T06:11:48Z","timestamp":1745820708000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10933-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10933"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10933-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5714337\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval and a review of the research proposal from the Institutional Review Boards of the participating institutions, including Kameda Medical Center (#21\u2013069\u2013230801), Seirei Hamamatsu Hospital (#3584), and Seirei Mikatahara Hospital (#21\u201358). This study was conducted in accordance with the principles of the Declaration of Helsinki. As this study was retrospective and the patient information was anonymized, the requirement for written informed consent was waived, and information regarding the right to opt out of the study was provided.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"531"}}